Targeting a specific protein to treat lung adenocarcinoma
Therapeutic Targeting of NSD2 in Lung Adenocarcinoma
['FUNDING_R01'] · UNIVERSITY OF TX MD ANDERSON CAN CTR · NIH-11085121
This study is looking at how a protein called NSD2 affects lung adenocarcinoma, the most common type of lung cancer, to help create a new treatment that could work better for patients by targeting this protein.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF TX MD ANDERSON CAN CTR (nih funded) |
| Locations | 1 site (HOUSTON, UNITED STATES) |
| Trial ID | NIH-11085121 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding how the protein NSD2 contributes to the progression of lung adenocarcinoma, the most common type of lung cancer. By investigating the mechanisms through which NSD2 operates, the researchers aim to develop a new therapy that targets this protein, potentially improving treatment outcomes for patients. The study will utilize advanced pre-clinical models to test the effectiveness of a novel NSD2 inhibitor, which could lead to a more effective treatment strategy that combines multiple therapeutic approaches. Patients may benefit from a more tailored and effective treatment plan that addresses the complexities of their cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with lung adenocarcinoma who have not responded adequately to existing treatments.
Not a fit: Patients with other types of lung cancer or those who are not diagnosed with lung adenocarcinoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective therapies for lung adenocarcinoma, improving survival rates and quality of life for patients.
How similar studies have performed: Previous research has shown promise in targeting similar epigenetic factors in cancer treatment, indicating potential for success in this approach.
Where this research is happening
HOUSTON, UNITED STATES
- UNIVERSITY OF TX MD ANDERSON CAN CTR — HOUSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: MAZUR, PAWEL K. — UNIVERSITY OF TX MD ANDERSON CAN CTR
- Study coordinator: MAZUR, PAWEL K.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancer Cause, Cancer Etiology, cancer metastasis, Cancer Model, cancer progression